{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "USD", "marketState": "REGULAR", "priceHint": 2, "regularMarketChange": 0.0, "regularMarketTime": 1683314012, "regularMarketDayHigh": 12.86, "regularMarketDayRange": "12.86 - 12.86", "regularMarketDayLow": 12.86, "regularMarketVolume": 739, "regularMarketPreviousClose": 12.86, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "fullExchangeName": "Other OTC", "financialCurrency": "AUD", "regularMarketOpen": 13.145, "averageDailyVolume3Month": 296, "averageDailyVolume10Day": 70, "fiftyTwoWeekLowChange": 3.3599997, "fiftyTwoWeekLowChangePercent": 0.3536842, "fiftyTwoWeekRange": "9.5 - 19.93", "fiftyTwoWeekHighChange": -7.0700006, "fiftyTwoWeekHighChangePercent": -0.35474163, "fiftyTwoWeekLow": 9.5, "fiftyTwoWeekHigh": 19.93, "trailingAnnualDividendRate": 0.04, "trailingPE": 47.629627, "trailingAnnualDividendYield": 0.00311042, "epsTrailingTwelveMonths": 0.27, "sharesOutstanding": 49410300, "bookValue": 2.817, "fiftyDayAverage": 12.8224, "fiftyDayAverageChange": 0.037599564, "fiftyDayAverageChangePercent": 0.0029323343, "twoHundredDayAverage": 13.577, "twoHundredDayAverageChange": -0.717, "twoHundredDayAverageChangePercent": -0.0528099, "marketCap": 671985152, "priceToBook": 4.5651402, "messageBoardId": "finmb_6117181", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketPrice": 12.86, "exchange": "PNK", "regularMarketChangePercent": 0.0, "shortName": "CLINUVEL PHARMACEUTICALS LTD", "longName": "Clinuvel Pharmaceuticals Limited", "firstTradeDateMilliseconds": 1234535400000, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "tradeable": false, "cryptoTradeable": false, "displayName": "Clinuvel Pharmaceuticals", "symbol": "CLVLF"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "535 Bourke Street", "address2": "Level 11", "city": "Melbourne", "state": "VIC", "zip": "3000", "country": "Australia", "phone": "61 3 9660 4900", "fax": "61 3 9660 4909", "website": "https://www.clinuvel.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PR\u00c9NUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.", "companyOfficers": [{"maxAge": 1, "name": "Dr. Philippe Jacques Wolgen M.B.A., M.D., MBA", "age": 59, "title": "CEO, MD & Director", "yearBorn": 1963, "fiscalYear": 2022, "totalPay": {"raw": 2435212, "fmt": "2.44M", "longFmt": "2,435,212"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Darren M. Keamy", "age": 49, "title": "CFO & Company Sec.", "yearBorn": 1973, "fiscalYear": 2022, "totalPay": {"raw": 274976, "fmt": "274.98k", "longFmt": "274,976"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Dennis J. Wright", "title": "Chief Scientific Officer", "fiscalYear": 2022, "totalPay": {"raw": 217092, "fmt": "217.09k", "longFmt": "217,092"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Lachlan  Hay", "title": "Director of Global Operations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Malcolm  Bull", "title": "Head of Investor Relations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 9, "boardRisk": 5, "compensationRisk": 9, "shareHolderRightsRisk": 7, "overallRisk": 7, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}